Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
Primary Purpose
Diabetic Polyneuropathy
Status
Completed
Phase
Phase 2
Locations
Thailand
Study Type
Interventional
Intervention
Capsaicin
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Polyneuropathy focused on measuring capsaicin, placebo, trial, diabetic polyneuropathy, neuropathic pain
Eligibility Criteria
Inclusion Criteria:
- History of type 2 Diabetes mellitus
- Peripheral neuropathy
- Stabilized on pain medication for at least one month
- No previous invasive intervention for pain relief
Exclusion Criteria:
- Local wound or skin abnormality in the applicable area
- Allergic to capsaicin
- Refuse to participate or give consent
- Has other significant disease or receive medication that may worsen neuropathy
Sites / Locations
- Thammasat University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Capsaicin
placebo
Arm Description
Outcomes
Primary Outcome Measures
Pain relief from pain score reduction, using visual analog scale (VAS)
Secondary Outcome Measures
Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)
Full Information
NCT ID
NCT00993070
First Posted
October 7, 2009
Last Updated
May 8, 2012
Sponsor
Thammasat University
Collaborators
Bangkok Drug company
1. Study Identification
Unique Protocol Identification Number
NCT00993070
Brief Title
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
Official Title
A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Thammasat University
Collaborators
Bangkok Drug company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Painful diabetic neuropathy is the most common cause of neuropathic pain. 0.075% topical capsaicin has been used to treat the pain, but there is no data in lower concentration. This is the efficacy and safety of 0.025% topical capsaicin in treatment of painful diabetic polyneuropathy.
Detailed Description
Patient is randomized to receive either 0.025% topical capsaicin or vehicle control (placebo) for 8 weeks. After one week wash-out period, patients will be switched to the other group for 8 weeks.
Outcome will be assessed by visual analog scale, neuropathic pain scale, SF-MPQ, SF-36. Safety and tolerability will be recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Polyneuropathy
Keywords
capsaicin, placebo, trial, diabetic polyneuropathy, neuropathic pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Capsaicin
Arm Type
Experimental
Arm Title
placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Capsaicin
Other Intervention Name(s)
Capsika gel
Intervention Description
0.025% topical capsaicin applied 4 times per day for 8 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
vehicle gel, applied 4 times per day for 8 weeks
Primary Outcome Measure Information:
Title
Pain relief from pain score reduction, using visual analog scale (VAS)
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of type 2 Diabetes mellitus
Peripheral neuropathy
Stabilized on pain medication for at least one month
No previous invasive intervention for pain relief
Exclusion Criteria:
Local wound or skin abnormality in the applicable area
Allergic to capsaicin
Refuse to participate or give consent
Has other significant disease or receive medication that may worsen neuropathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kongkiat Kulkantrakorn, MD
Organizational Affiliation
Thammasat University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thammasat University Hospital
City
Pathumthani
ZIP/Postal Code
12120
Country
Thailand
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
We'll reach out to this number within 24 hrs